What it is
Thymalin is not a single peptide with one defined sequence, the way BPC-157 or Semax are. It is a complex of low-molecular-weight peptides extracted from calf thymus, developed in the early 1980s by Vladimir Khavinson's group at what is now the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to a family of Russian-developed "peptide bioregulators" that includes Epithalamin (pineal-derived) and several other tissue-specific extracts, all studied by overlapping groups of the same researchers.
That origin matters for how to read the evidence. Almost all of the published research on Thymalin comes out of Russian institutes, much of it in Russian-language journals, and it sits largely outside the Western clinical-trial literature that covers most compounds on this site.
What its own research measured
The earliest work is Khavinson and Morozov's 1982 paper in the Soviet Military Medical Journal, describing the experimental and clinical development of Thymalin as an immunoregulator.[1] Kuznik and colleagues followed in 1984 with a study in patients with ischemic heart disease, published in Farmakologiya i Toksikologiya, examining Thymalin's effect on immune status and blood clotting measures in that population.[2]
The longest-running claim attached to Thymalin is geroprotection. Khavinson and Morozov, writing in Neuroendocrinology Letters in 2003, reported on a cohort of 266 elderly and older adults followed for six to eight years, tracking Thymalin and Epithalamin together against measures of cardiovascular, endocrine, immune and nervous system function.[3] A later 2013 review by Khavinson, Kuznik and Ryzhak in Advances in Gerontology summarized this and other bioregulator work as evidence for slowing age-related decline, but reviews written by the same group that develops the compound are not independent evidence, and no trial of this kind has been replicated outside that research network.[4]
How to weigh this evidence
Two things can be true at once here. The immune-modulation research on thymic peptides generally, including better-characterized relatives like thymosin alpha 1, has a real mechanistic basis, and Thymalin's early clinical work follows a defensible line of inquiry for its era. At the same time, most of the human data is decades old, comes from one research group, and has not been independently replicated in a randomized, placebo-controlled design that would meet the bar set by more recent thymic-peptide work. Anyone evaluating it should treat "extensively studied in Russia" and "independently replicated" as two different claims.
No vendor is currently listing this
Thymalin isn't available from any vendor we currently track. It was last seen at $4.50 per mg on Penguin Peptides, 2 July 2026, listed as a 10 mg vial for $45.00. That figure is included here for reference. It's what the compound was actually selling for the last time we confirmed a listing, not a price you can act on today. If a vendor relists it, this page will reflect the live price the next time our data updates.
References
- [1] Khavinson VKh, Morozov VG. [Experimental and clinical study of a new immunoregulator preparation thymalin]. Voen Med Zh. 1982;(5):37-39. PubMed ↗
- [2] Kuznik BI et al. [Thymalin as a modulator of immunogenesis and hemostasis]. Farmakol Toksikol. 1984;47(1):67-71.
- [3] Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PubMed ↗
- [4] Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: A new class of geroprotectors. Message 1: Results of experimental studies. Adv Gerontol. 2013;3:225-235.